Project description
Novel breast cancer diagnostic test for personalised treatment
Breast cancer (BC) is the most common cancer in women worldwide, but current diagnostic tests lack precision, often leading to misdiagnosis and inaccurate treatment. The goal of the EU-funded Multiplex8+ project is the development of a personalised and precise diagnostic test for early and late-stage BC. The test combines two patented multiplexed cancer diagnostic technologies: visualisation (RNA FISH) and RNA sequencing. The combination of these technologies will help to eliminate misdiagnosis and will enable a specific BC barcode system to suggest a particular personalised treatment and estimate its length and prognostic value. The current project stage involves establishing an accredited laboratory for clinical validation followed by the creation of the first high-value biotech company in Slovakia.
Objective
Breast cancer (BCa) is the most common cancer in women worldwide with 2.1M new cases diagnosed annually, and this number is expected to double in 2030. However, today’s diagnostic tests lack precision and, as a result, many BCa patients are misdiagnosed then treated inaccurately, putting their lives at risk while creating undue problems for families and healthcare systems. MultiplexDX (a leading Slovak biotechnology company) proposes a personalized and precise diagnostic test for early and late stage BCa called Multiplex8+. The test combines two IP-protected, revolutionary and multiplexed cancer diagnostic technologies, visualization (RNA FISH) and RNA sequencing. By combining the two technologies to eliminate misdiagnosis, Multiplex8+ defines a specific BCa barcode that suggests a specific personalized treatment, length of therapy and clarifies how likely will a BCa patient benefit from chemotherapy or not.
There are 2 main objectives of this project: 1. Establish an ISO-15189 accredited laboratory to provide diagnostic services to cancer centers (B2B) and additionally to patients (B2C). A clinical validation on 4 000 tissue samples will be conducted to obtain clinically-based evidence; 2. Build the first successful high-value biotech company in Slovakia. The company has already raised €2,05M in seed investments and grants and started sales of subproducts generating €300k in revenues since 2016. MultiplexDX is operating in the Comenius University Science Park in Bratislava and consists of 17 team members, 5 business and 7 scientific advisors. Our planned accumulated revenues in the first 5 years are €305,3M, generating a net profit of €133,0M and representing a ROI of 10,3. Importantly, Multiplex8+ is supported by the entire oncology value chain (patient associations, cancer centers, hospitals, KOLs, insurance companies, pharma/medtech, clinical laboratories, biobanks, investors, etc.).
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology breast cancer
- engineering and technology medical engineering medical laboratory technology diagnostic technologies
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
841 04 Bratislava
Slovakia
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.